Supportive Care in Cancer

, Volume 18, Issue 9, pp 1115–1121 | Cite as

Communication and informed consent in phase 1 trials: a review of the literature from January 2005 to July 2009

  • Valerie A. Jenkins
  • John L. Anderson
  • Lesley J. Fallowfield
Review Article

Abstract

Objective and methods

A review conducted in 2005 identified many of the communication difficulties experienced by patients and doctors when discussing phase 1 (P1) oncology trials. The current paper is an update of the area and focuses on studies that measure patient comprehension of information given during the P1 trial discussion and ways to enhance understanding. A literature search was performed for relevant articles published between January 2005 and July 1st 2009.

Results

Only 12/109 studies met the criteria for inclusion in the review. One study recorded the actual trial discussion and compared patients’ understanding with what the clinician had communicated. The others used interview techniques and surveys to elicit patients’ understanding of P1 trials, motivations for considering trials and expectations of benefit. Two examined interventions to aid patient understanding.

Conclusion

Explaining potential participation in a P1 trial with a patient with cancer is not an easy task: the doctor must ensure that the patient has an accurate understanding of their condition and that standard treatments have now been exhausted. This must be followed by admission of the probable lack of any therapeutic benefit from the P1 drug together with the possibility that there might be unwanted side effects, many of which are unknown. These are all challenging subjects. New educational initiatives informed through research conducted with patients and health care professionals are currently being developed and clearly much needed.

Keywords

Phase 1 oncology trials Patient understanding Informed consent 

Notes

Acknowledgements

Cancer Research UK funded all the authors.

References

  1. 1.
    Ho J et al (2006) Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital. BMC Cancer 6:263CrossRefPubMedGoogle Scholar
  2. 2.
    Christakis NA (1999) Death foretold: Prophecy and prognosis in medical care. Chicago, University of Chicago Press, p 328Google Scholar
  3. 3.
    Cox AC, Fallowfield LJ, Jenkins VA (2006) Communication and informed consent in phase 1 trials: a review of the literature. Support Care Cancer 14(4):303–309CrossRefPubMedGoogle Scholar
  4. 4.
    Appelbaum PS, Roth LH, Lidz C (1982) The therapeutic misconception: informed consent in psychiatric research. Int J Law Psychiatry 5(3–4):319–329CrossRefPubMedGoogle Scholar
  5. 5.
    Henderson GE et al (2006) Therapeutic misconception in early phase gene transfer trials. Soc Sci Med 62(1):239–253CrossRefPubMedGoogle Scholar
  6. 6.
    Miller FG, Joffe S (2008) Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option? Clin Trials 5(6):617–623CrossRefPubMedGoogle Scholar
  7. 7.
    Arkenau HT et al (2008) Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer 98(6):1029–1033CrossRefPubMedGoogle Scholar
  8. 8.
    Kass N et al (2008) Purpose and benefits of early phase cancer trials: what do oncologists say? What do patients hear? J Empir Res Hum Res Ethics 3(3):57–68CrossRefPubMedGoogle Scholar
  9. 9.
    Agrawal M et al (2006) Patients’ decision-making process regarding participation in phase I oncology research. J Clin Oncol 24(27):4479–4484CrossRefPubMedGoogle Scholar
  10. 10.
    Cohen MZ et al (2007) Phase I participants’ views of quality of life and trial participation burdens. Support Care Cancer 15(7):885–890CrossRefPubMedGoogle Scholar
  11. 11.
    Weinfurt KP et al (2008) Expectations of benefit in early-phase clinical trials: implications for assessing the adequacy of informed consent. Med Decis Making 28(4):575–581CrossRefPubMedGoogle Scholar
  12. 12.
    Flynn KE et al (2008) Decisional conflict among patients who accept or decline participation in phase I oncology studies. J Empir Res Hum Res Ethics 3(3):69–77CrossRefPubMedGoogle Scholar
  13. 13.
    Nurgat ZA et al (2005) Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br J Cancer 92(6):1001–1005CrossRefPubMedGoogle Scholar
  14. 14.
    Strevel EL et al (2007) The impact of an educational DVD on cancer patients considering participation in a phase I clinical trial. Support Care Cancer 15(7):829–840CrossRefPubMedGoogle Scholar
  15. 15.
    Weinfurt KP et al (2005) Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trials. Cancer 103(1):140–147CrossRefPubMedGoogle Scholar
  16. 16.
    Kass NE et al (2009) An intervention to improve cancer patients’ understanding of early-phase clinical trials. Irb 31(3):1–10PubMedGoogle Scholar
  17. 17.
    Finlay E et al (2009) Do phase 1 patients have greater needs for palliative care compared with other cancer patients? Cancer 115(2):446–453CrossRefPubMedGoogle Scholar
  18. 18.
    Arkenau HT et al (2009) Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer. Oncology 76(3):151–156CrossRefPubMedGoogle Scholar
  19. 19.
    Carlson LE, Bultz BD, Morris DG (2005) Individualized quality of life, standardized quality of life, and distress in patients undergoing a phase I trial of the novel therapeutic Reolysin (reovirus). Health Qual Life Outcomes 3:7CrossRefPubMedGoogle Scholar
  20. 20.
    Finlay E, Casarett D (2009) Making difficult discussions easier: using prognosis to facilitate transitions to hospice. CA Cancer J Clin 59(4):250–263CrossRefPubMedGoogle Scholar
  21. 21.
    Joffe S, Miller FG (2006) Rethinking risk-benefit assessment for phase I cancer trials. J Clin Oncol 24(19):2987–2990CrossRefPubMedGoogle Scholar
  22. 22.
    Weinfurt KP (2008) Varieties of uncertainty and the validity of informed consent. Clin Trials 5(6):624–625, discussion 630CrossRefPubMedGoogle Scholar
  23. 23.
    Tomamichel M et al (1995) Informed consent for phase I studies: evaluation of quantity and quality of information provided to patients. Ann Oncol 6(4):363–369PubMedGoogle Scholar
  24. 24.
    Siminoff LA, Fetting JH (1989) Effects of outcome framing on treatment decisions in the real world: impact of framing on adjuvant breast cancer decisions. Med Decis Making 9(4):262–271CrossRefPubMedGoogle Scholar
  25. 25.
    Kass NE (2008) Early phase clinical trials: communicating the uncertainties of ‘magnitude of benefit’ and ‘likelihood of benefit’. Clin Trials 5(6):627–629CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Valerie A. Jenkins
    • 1
  • John L. Anderson
    • 1
  • Lesley J. Fallowfield
    • 1
  1. 1.Cancer Research UK Psychosocial Oncology GroupBrighton and Sussex Medical School, University of SussexBrightonUK

Personalised recommendations